Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy

Abstract Background The major breakthrough in cancer therapy with immune checkpoint inhibitors (ICIs) has highlighted the important role of immune checkpoints in antitumoral immunity. However, most patients do not achieve durable responses, making biomarker research in this setting essential. CD27 i...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Joao Gorgulho, Sven H. Loosen, Ramsha Masood, Franziska Giehren, Francesca Pagani, Gustav Buescher, Lorenz Kocheise, Vincent Joerg, Constantin Schmidt, Kornelius Schulze, Christoph Roderburg, Eva Kinkel, Britta Fritzsche, Simon Wehmeyer, Benjamin Schmidt, Paul Kachel, Christina Rolling, Julian Götze, Alina Busch, Marianne Sinn, Thais Pereira-Veiga, Harriet Wikman, Maria Geffken, Sven Peine, Urte Matschl, Markus Altfeld, Samuel Huber, Ansgar W. Lohse, Fabian Beier, Tim H. Brümmendorf, Carsten Bokemeyer, Tom Luedde, Johann von Felden
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2024-11-01
Ráidu:	Journal of Experimental & Clinical Cancer Research
Fáttát:	PD-1 Liquid biopsy Immunotherapy Soluble immune checkpoints Prognosis Biomarker
Liŋkkat:	https://doi.org/10.1186/s13046-024-03215-4
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!